Travere Therapeutics, a San Diego-based biopharmaceutical company focused on rare kidney and metabolic diseases, has been one of the strongest performers in the biotech sector over the past year, rallying from approximately $15 to above $55. Against this backdrop, investors are increasingly asking whether TVTX can reach $70 per share—the highest price target on Wall Street, maintained by Citigroup analyst Yigal Nochomovitz following an upgrade from $62 in mid-2026. The $70 target has become a focal point because it represents both a psychological round number and the ceiling of current analyst expectations.
Travere Therapeutics develops and commercializes therapies for rare diseases, with its flagship product FILSPARI (sparsentan) now approved for two indications: IgA nephropathy (IgAN), a progressive kidney disease, and focal segmental glomerulosclerosis (FSGS), where FILSPARI became the first FDA-approved medication following a landmark regulatory decision. The company also markets Thiola and Thiola EC for cystinuria. With a market capitalization of approximately $5.1 billion and trailing twelve-month revenue of roughly $536 million—up 96% year-over-year—Travere recently reported its first non-GAAP profitable quarter in Q1 2026, an important inflection point for a company historically deep in investment mode.
Several catalysts underpin the bull case for TVTX reaching $70. FILSPARI's commercial momentum remains robust, with U.S. net product sales surpassing $100 million in a single quarter and patient demand continuing to accelerate in IgAN. The label expansion into FSGS opens an estimated 40,000-patient addressable market in the United States alone, with cross-selling synergies from Travere's existing nephrology sales infrastructure.
Additionally, the United States Patent and Trademark Office issued a Notice of Allowance covering the IgAN dosing application, extending expected U.S. patent coverage into October 2037. This meaningfully reduces the intellectual property overhang that had weighed on long-term revenue modeling. Separately, the licensing deal with Everest Medicines for civorebrutinib—an oral BTK inhibitor—diversifies the pipeline and gives analysts additional grounds to raise their valuation assumptions.
Wall Street sentiment remains overwhelmingly positive. Of 15 analysts covering the stock, 12 rate it a Strong Buy, 2 rate it Buy, and only 1 maintains a Hold. Guggenheim, Wells Fargo, H.C. Wainwright, and Wedbush have all raised price targets into the $61–$67 range in recent months, with Citigroup's $70 target capping the consensus range.
The primary risk is valuation and elevated expectations. After rallying more than 260% over the past year, TVTX already reflects substantial optimism about FILSPARI's commercial trajectory and pipeline potential. The stock trades at approximately 9.5 times trailing sales, and while the forward price-to-earnings (P/E) ratio of roughly 22 times appears reasonable, it depends heavily on earnings materializing as projected.
Competition in the IgAN market is intensifying. Novartis and other large-cap pharmaceutical companies are advancing their own nephrology candidates, and any data readouts suggesting superior efficacy or safety from competing therapies could challenge FILSPARI's market position. Additionally, Travere remains in the early stages of its profitability transition; any commercial execution missteps during the FSGS launch could disrupt the earnings trajectory that underpins elevated price targets.
From a technical standpoint, the stock already trades just below its 52-week high of $60.10, which serves as immediate resistance. A failure to break and hold above $60 could signal exhaustion after an extraordinary run, while a sustained move through that level would place $70 within range as the next major psychological and analytical target.
The $60 level represents a critical resistance zone—it marks the 52-week high and the area where sellers have previously emerged. A decisive breakout above $60 on elevated volume would confirm continued bullish momentum and shift the technical narrative toward targeting higher levels, with $65 and $70 becoming the next logical milestones. On the downside, support appears in the $48–$50 zone, which aligns with prior consolidation and multiple analyst target revisions. The long-term trend structure remains bullish, underpinned by a series of higher lows stretching back to mid-2025.
The analyst community is nearly unanimous in its constructive outlook. The average 12-month price target stands at approximately $59, with individual targets ranging from Piper Sandler's $49 to Citigroup's $70. Recent target increases have been driven by the FSGS approval, the civorebrutinib deal, and extended FILSPARI patent protection. Guggenheim lifted its target from $56 to $65 in June 2026, while Wells Fargo moved from $50 to $65. The only notable cautionary note comes from J.P. Morgan, which trimmed its target slightly in early 2026 but maintains an Overweight rating—suggesting even the most conservative bulls remain constructive.
Navigating a volatile biotech stock like Travere Therapeutics requires timely and data-driven decision-making. Tickeron's AI Daily Buy/Sell Signals continuously monitor thousands of stocks and ETFs, using artificial intelligence to generate Buy, Sell, or Hold signals based on evolving technical patterns, market conditions, and AI-driven analysis. These signals help traders identify emerging opportunities, manage existing positions with greater confidence, and stay ahead of shifting market trends without manually screening through endless charts. For investors looking to incorporate real-time intelligence into their trading workflow, the platform offers a streamlined way to track opportunities across the market. Explore AI Daily Buy/Sell Signals to see how AI can complement your investment process.
The $70 price target for Travere Therapeutics appears ambitious but not unrealistic given the company's commercial momentum, expanded FILSPARI label, extended intellectual property runway, and a pipeline that now includes civorebrutinib. Achieving this level would likely require flawless execution on the FSGS launch, continued revenue growth above 20–25% annually, a clear path to sustained GAAP profitability, and no disruptive competitive entries in the IgAN space. The primary risks center on valuation—much of the good news may already be priced in after a 260% rally—and the inherent uncertainty of commercial-stage biotech execution. Investors should monitor quarterly FILSPARI sales trends, FSGS launch metrics, and the stock's ability to break above the $60 resistance level as key signposts on the road to $70.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, TVTX has been loosely correlated with MGTX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if TVTX jumps, then MGTX could also see price increases.
| Ticker / NAME | Correlation To TVTX | 1D Price Change % | ||
|---|---|---|---|---|
| TVTX | 100% | -0.49% | ||
| MGTX - TVTX | 42% Loosely correlated | +1.91% | ||
| VCYT - TVTX | 37% Loosely correlated | N/A | ||
| WVE - TVTX | 36% Loosely correlated | +1.52% | ||
| LGND - TVTX | 36% Loosely correlated | -0.80% | ||
| GERN - TVTX | 35% Loosely correlated | -3.68% | ||
More | ||||